{"id":9581,"date":"2026-06-01T14:55:04","date_gmt":"2026-06-01T06:55:04","guid":{"rendered":"https:\/\/chimebiologics.com\/?p=9581"},"modified":"2026-06-01T15:32:07","modified_gmt":"2026-06-01T07:32:07","slug":"daewoong-pharmaceutical-press-release-26","status":"publish","type":"post","link":"https:\/\/chimebiologics.com\/ja\/daewoong-pharmaceutical-press-release-26\/","title":{"rendered":"(English) Chime Biologics and Daewoong Pharmaceutical Enter Strategic Partnership to Advance Dupilumab Biosimilar Development and Commercialization in Global Markets"},"content":{"rendered":"

\u7533\u3057\u8a33\u3042\u308a\u307e\u305b\u3093\u3001\u3053\u306e\u30b3\u30f3\u30c6\u30f3\u30c4\u306f\u305f\u3060\u4eca\u3000English<\/a>\u3068 \u4e2d\u6587<\/a>\u3000\u306e\u307f\u3067\u3059\u3002 For the sake of viewer convenience, the content is shown below in this site default language. You may click one of the links to switch the site language to another available language.<\/p>

<\/p>\n

Chime Biologics and Daewoong Pharmaceutical Enter Strategic Partnership to Advance Dupilumab Biosimilar Development and Commercialization in Global Markets<\/strong><\/h1>\n

Wuhan, China & Seoul, South Korea | June 2, 2026<\/strong> \u2014 Chime Biologics, a global biologics CDMO dedicated to enabling partners\u2019 success, and Daewoong Pharmaceutical, a leading South Korean pharmaceutical company, today announced the signing of a strategic partnership agreement for the development and manufacturing of a dupilumab biosimilar candidate referencing Dupixent.<\/p>\n

\"\"

(From left) Seongsoo Park, CEO of Daewoong Pharmaceutical, and Jimmy Wei, Board Director and CEO of Chime Biologics, pose for a commemorative photo at the signing ceremony for strategic agreements on the development of a biosimilar referencing Dupixent.<\/p><\/div>\n

Through this partnership, Chime Biologics will leverage its extensive end-to-end biosimilar development and commercialization experiences, advanced AI-enabled development platform (Chime AI Platform), and the rapidly evolving bioprocess supply chain ecosystem in China (Chime Innovation Alliance) to support Daewoong Pharmaceutical\u2019s global biosimilar ambitions. The partnership reflects both companies\u2019 commitment to delivering high-quality and accessible biologic medicines to patients worldwide.<\/p>\n

The dupilumab biosimilar marks Daewoong Pharmaceutical\u2019s full-fledged entry into the biosimilar sector as a key long-term growth engine. Referencing Dupixent, one of the world\u2019s best-selling biologics co-developed by Sanofi and Regeneron Pharmaceuticals, the program targets a rapidly expanding global immunology market driven by increasing demand for therapies treating atopic dermatitis and other Type 2 inflammatory diseases.<\/p>\n

According to industry estimates, Dupixent achieved approximately US$17.8 billion in global sales in 2025, reinforcing its position as a blockbuster biologic and a highly attractive target for biosimilar development.<\/p>\n

\"\"

(From left) SeungSuh Hong, Head of the Biosimilar Business Division at Daewoong Pharmaceutical, Seongsoo Park, CEO of Daewoong Pharmaceutical, Benny Chong, Chairman of VMS, and Jimmy Wei, Board Director and CEO of Chime Biologics, pose for a commemorative photo.<\/p><\/div>\n

\u201cDaewoong Pharmaceutical is committed to building a globally competitive biosimilar business as part of our future growth strategy,\u201d said Seongsoo Park, Chief Executive Officer of Daewoong Pharmaceutical.<\/strong> \u201cStarting with dupilumab, we aim to establish a differentiated biosimilar portfolio for global markets. Through this partnership, we expect to strengthen our development and manufacturing capabilities while accelerating our entry into the global biosimilar market. We believe this partnership will create a powerful foundation for our long-term biosimilar journey.\u201d<\/p>\n

Jimmy Wei, Board Director and Chief Executive Officer of Chime Biologics<\/strong>, commented: \u201cWe are honored to become Daewoong Pharmaceutical\u2019s strategic partner for its entry into the global biosimilar market. Biosimilars have evolved into a highly competitive arena requiring not only scientific excellence and manufacturing robustness, but also speed, cost efficiency, and global regulatory expertise. Combining Chime Biologics\u2019 end-to-end biologics development and manufacturing platform with AI-driven innovation and China\u2019s rapidly advancing supply chain ecosystem, we are determined to help Daewoong Pharmaceutical emerge as a strong global biosimilar player.\u201d<\/p>\n

The companies expect the partnership to serve as the foundation for potential future collaborations to embrace the upcoming era of biosimilars in the global biopharma market.<\/p>\n

\"\"

Representatives from Daewoong Pharmaceutical and Chime Biologics pose for a commemorative photo.<\/p><\/div>\n

About Chime Biologics<\/b><\/strong><\/p>\n

Chime Biologics is a leading global CDMO, focused on ensuring our customers' success in delivering innovative biologics as well as biosimilars to patients across the world. Chime Biologics can support customers end to end, from pre-clinical support and cell line development through to clinical and commercial manufacturing of drug substance and drug product. Employing our state-of-the-art capabilities in our Europe Innovation Hub (Basel, CH), China Innovation Hub (Shanghai, CN), Development & Manufacturing Campus (Wuhan, CN) and proven success in supporting our clients with their clinical and commercial authorizations across the globe, Chime Biologics is a true end-to-end solution provider for the biologics industry. With over 600 skilled employees, we share a common goal to make cutting-edge biologics affordable and accessible to patients worldwide, fulfilling our commitment to improving human health globally.<\/p>\n

For more information, please visit www.chimebiologics.com.<\/p>\n

About Daewoong Pharmaceutical<\/strong><\/p>\n

Daewoong Pharmaceutical is a leading healthcare company headquartered in South Korea, committed to improving patients\u2019 quality of life through innovation in pharmaceuticals, biologics, and healthcare solutions. The company operates across global markets with a diversified portfolio spanning prescription medicines, biologics, medical devices, and consumer healthcare products. Daewoong Pharmaceutical continues to expand its global presence through research and development, strategic partnerships, and advanced manufacturing capabilities.<\/p>\n

\u00a0<\/strong><\/p>\n

About Dupilumab (Dupixent)<\/strong><\/p>\n

Dupilumab (Dupixent) is a fully human monoclonal antibody targeting the IL-4 receptor alpha subunit, inhibiting IL-4 and IL-13 signaling pathways that play central roles in Type 2 inflammation. The product is approved in multiple countries for the treatment of atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, and other inflammatory diseases. Co-developed by Sanofi and Regeneron Pharmaceuticals, Dupixent has become one of the world\u2019s top-selling biologic medicines.<\/p>\n

<\/p>\n<\/div><\/section><\/div>\n